Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-6 Regulation of Metabolism in Obesity
NCT03967691Completed
- Sponsor
- Rigshospitalet
- Start
- Jun 2019
- Primary completion
- Apr 2020
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Single-blind trial of tocilizumab in obesity (2 arms), sponsored by Rigshospitalet. Primary endpoint: Lipolytic rate. Started Jun 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03967691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03967691.